Highlights

  • Racura Oncology shares rose 8.27% to AUD 2.75 on 15 May 2026 following a clinical trial update.
  • The company received approval to progress its CPACS Phase 1 trial to the next RC220 dose level.
  • No dose-limiting toxicities or treatment-related safety concerns were identified in Cohort 1.
  • Patient screening for Cohort 2 is now underway across Australia, Hong Kong and South Korea.
  • The updated trial protocol will also assess RC220’s cardioprotective potential

Racura Oncology Ltd (ASX:RAC) shares climbed 8.27% to AUD 2.75 during the afternoon session on 15 May 2026 after the company announced a key milestone in its CPACS Phase 1 clinical trial program. The stock has now gained 93.66% over the past year, with investors responding positively to the latest safety review outcome for the company’s RC220 oncology program.

The company confirmed that its Safety Review Committee (SRC) had approved progression of the CPACS trial to the next designated RC220 dose level following evaluation of patient safety and pharmacokinetic data from the initial cohort.

According to the announcement, the review identified no treatment-related safety concerns or dose-limiting toxicities among the first three patients treated in Cohort 1.

The favourable review outcome allows the study to proceed to Cohort 2, where patients will receive an increased RC220 dose of 80mg/m².

Trial Progress Marks Important Clinical Development Step

The CPACS trial represents one of Racura Oncology’s key clinical programs focused on evaluating RC220 in combination with the chemotherapy drug doxorubicin.

The study is investigating both anticancer activity and the potential cardioprotective effects of RC220 in patients with advanced metastatic solid tumours.

Under the completed Cohort 1 treatment protocol, patients initially received RC220 alone at a 40mg/m² dose level before progressing to combination treatment cycles involving RC220 and standard-of-care doxorubicin at 60mg/m².

The company stated that all patients enrolled in the study remain alive despite having advanced metastatic cancers at the time of enrolment.

Management described the absence of dose-limiting toxicities during the observation period as an encouraging outcome for the ongoing development program.

The latest safety clearance therefore represents an important step in advancing the trial through its early-stage dose escalation process.

Patient Recruitment Expands Across Multiple Regions

Following the SRC decision, Racura has now commenced screening eligible patients for enrolment into Cohort 2.

The recruitment process is underway across Australia, Hong Kong and South Korea.

The expanded cohort will evaluate the higher 80mg/m² RC220 dose level under an updated trial protocol.

According to the company, the revised protocol introduces an initial lead-in safety monotherapy cycle using doxorubicin before administration of RC220.

This change is intended to support assessment of RC220’s potential cardioprotective effects through a blood-based molecular testing approach.

Racura previously referenced this molecular testing strategy in an earlier February 2026 announcement.

Existing Cohort 1 patients who remain on treatment are also expected to transition to the updated protocol for future treatment cycles.

Safety Review Outcome Supports Ongoing Dose Escalation

Phase 1 oncology trials typically focus heavily on safety monitoring and dose optimisation.

The role of the Safety Review Committee is particularly important during this process because it independently evaluates clinical data before approving progression to higher dosing levels.

According to Racura, the SRC reviewed adverse events, laboratory findings, pharmacokinetic information and broader patient observations before determining the study could safely proceed.

The company noted that no significant safety concerns emerged during evaluation of the first patient group.

This outcome supports continuation of the trial’s structured dose-escalation framework designed to evaluate the safety profile of RC220 both alone and in combination with chemotherapy.

Clinical-stage biotechnology investors often monitor these types of safety milestones closely because favourable early-stage safety outcomes can reduce development uncertainty for investigational therapies.

Focus on Cardioprotection and Anticancer Activity

One of the differentiating aspects of the CPACS trial is its dual focus on both cancer treatment effectiveness and cardioprotection.

Anthracycline chemotherapy drugs such as doxorubicin are widely used in oncology but can sometimes lead to cardiotoxicity in patients.

Racura is exploring whether RC220 may help address this challenge while also enhancing anticancer activity.

The company’s updated trial design incorporating blood-based molecular testing aims to provide additional insight into these cardioprotective properties.

If successfully demonstrated in future studies, the approach may potentially broaden the commercial and clinical relevance of the RC220 program.

However, the company also noted that the trial remains in the early clinical stages, and additional testing, validation and future studies will still be required.

Management Highlights Clinical Progress

Racura Oncology Chief Executive Officer and Managing Director Dr Daniel Tillett described the milestone as an important achievement for the company and its clinical collaborators.

Management highlighted the safety profile observed to date, particularly the lack of dose-limiting toxicities despite combining RC220 with standard-dose doxorubicin.

The company also acknowledged the contribution of participating patients and their families during the trial process.

Racura stated that the ongoing progress of the CPACS study continues supporting broader development efforts for RC220 across multiple oncology indications.

Racura Continues Broader Oncology Development Strategy

Beyond the CPACS program, Racura Oncology is also advancing RC220 across additional cancer indications.

The company describes itself as a clinical-stage biopharmaceutical Business focused on developing therapies targeting cancer growth regulators.

Its lead asset, (E,E)-bisantrene, forms the basis of the proprietary RC220 formulation currently under development.

According to the company, the therapy has demonstrated therapeutic activity alongside an established safety profile in previous studies.

Racura is currently progressing several clinical programs involving RC220, including development activities in acute myeloid leukaemia (AML), mutant epidermal growth Factor receptor non-small cell lung cancer (EGFRm NSCLC), and combination oncology therapies.

The company has also established research collaborations with multiple universities and medical institutions internationally.

Investors Monitor Clinical Milestones Closely

Biotechnology stocks often experience heightened market attention around clinical trial milestones because these updates can significantly influence development timelines and future commercial potential.

The latest announcement appears to have strengthened investor confidence regarding the ongoing progression of the CPACS program.

The ability to move safely into a higher dose cohort represents an important procedural milestone in Phase 1 clinical development.

At the same time, investors are likely to continue monitoring future patient recruitment progress, additional safety observations and any early efficacy signals that may emerge from later-stage trial updates.

The company’s focus on both anticancer activity and cardioprotection may also remain an area of interest as the trial advances further through clinical evaluation.